

WEST Search History

DATE: Monday, October 13, 2003

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ</i>			
L4	C1-esterase inhibitor.clm.	7	L4
L3	L2 and Escherichia	4	L3
L2	C1-esterase inhibitor	50	L2
L1	E. coli C1-esterase inhibitor	0	L1

END OF SEARCH HISTORY

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 7 of 7 returned.**☐ 1. Document ID: US 20020131933 A1

L4: Entry 1 of 7

File: PGPB

Sep 19, 2002

PGPUB-DOCUMENT-NUMBER: 20020131933
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020131933 A1

TITLE: Biopolymer membrane and methods for its preparation

PUBLICATION-DATE: September 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Delmotte, Yves	Neufmaison		BE	

US-CL-CURRENT: [424/1.11](#); [424/130.1](#), [424/443](#), [424/94.64](#), [514/2](#), [514/54](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	Image
Grant Desc	Image										

☐ 2. Document ID: US 20020073438 A1

L4: Entry 2 of 7

File: PGPB

Jun 13, 2002

PGPUB-DOCUMENT-NUMBER: 20020073438
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020073438 A1

TITLE: Methods of purifying human acid alpha-glucosidase

PUBLICATION-DATE: June 13, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Reuser, Arnold J.	Rotterdam		NL	
Van der Ploeg, Ans T.	Poortugaal		NL	

US-CL-CURRENT: [800/7](#); [435/208](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	Image
Grant Desc	Image										

☐ 3. Document ID: US 6090777 A

L4: Entry 3 of 7

File: USPT

Jul 18, 2000

US-PAT-NO: 6090777
DOCUMENT-IDENTIFIER: US 6090777 A
**** S e image for Certificate of Correction ****

TITLE: Method to reduce myocardial injury during acute myocardial infarction

DATE-ISSUED: July 18, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hack; Cornelis Erik	Diemen			NL
Hermens; Willem Theodoor	Gronsveld			NL

US-CL-CURRENT: 514/2; 514/8, 530/380, 530/417

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	End
Draw Desc	Image									

☐ 4. Document ID: US 5747532 A

L4: Entry 4 of 7

File: USPT

May 5, 1998

US-PAT-NO: 5747532
DOCUMENT-IDENTIFIER: US 5747532 A

TITLE: Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor

DATE-ISSUED: May 5, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lai; Ching-San	Encinitas	CA		

US-CL-CURRENT: 514/491; 424/145.1, 424/158.1, 424/93.7, 514/162, 514/171, 514/305, 514/313, 514/352, 514/4, 514/45

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	End
Draw Desc	Image									

☐ 5. Document ID: US 5733885 A

L4: Entry 5 of 7

File: USPT

Mar 31, 1998

US-PAT-NO: 5733885
DOCUMENT-IDENTIFIER: US 5733885 A

TITLE: Method of producing a virus-safe biological preparation

DATE-ISSUED: March 31, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Eibl; Johann	Vienna			AT
Hummel; Gabriela	Vienna			AT
Redl; Gerda	Rutzendorf			AT
Seelich; Thomas	Vienna			AT
Turecek; Peter	Vienna			AT
Wober; Gunter	Oberwaltersdorf			AT

US-CL-CURRENT: 514/21; 422/28, 422/30, 422/32, 435/236, 435/238, 514/12, 514/8,
530/364, 530/380, 530/390.1, 530/416, 530/427, 530/830

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Print
Draw Desc	Image									

☐ 6. Document ID: US 5681750 A

L4: Entry 6 of 7

File: USPT

Oct 28, 1997

US-PAT-NO: 5681750

DOCUMENT-IDENTIFIER: US 5681750 A

TITLE: Process for preparing a C1-esterase inhibitor concentrate (C1-INH), and concentrate obtained, for therapeutic use

DATE-ISSUED: October 28, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Pouille; Michel	Wavrin			FR
Burnouf (nee Radosevich); Miryana	Wavrin			FR

US-CL-CURRENT: 436/86; 435/188, 435/2, 436/175, 436/178, 436/821, 436/825

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Print
Draw Desc	Image									

☐ 7. Document ID: US 4388232 A

L4: Entry 7 of 7

File: USPT

Jun 14, 1983

US-PAT-NO: 4388232

DOCUMENT-IDENTIFIER: US 4388232 A

**** See image for Certificate of Correction ****

TITLE: Method of producing plasma fractions free of side-effects using fast-reacting antithrombin

DATE-ISSUED: June 14, 1983

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Eibl; Johann	Vienna			AT
Elsinger; Fritz	Vienna			AT
Linnau; Yendra	Vienna			AT

US-CL-CURRENT: 530/383; 424/530, 530/380, 530/381, 530/387.1, 530/393, 530/830

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Full
Original	Draw	Image								

Generate Collection Print

Terms	Documents
C1-esterase inhibitor.clm.	7

Display Format: Change Format

[Previous Page](#) [Next Page](#)

WESTGenerate CollectionPrint

L4: Entry 3 of 7

File: USPT

Jul 18, 2000

US-PAT-NO: 6090777

DOCUMENT-IDENTIFIER: US 6090777 A

**** See image for Certificate of Correction ****

TITLE: Method to reduce myocardial injury during acute myocardial infarction

DATE-ISSUED: July 18, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hack; Cornelis Erik	Diemen			NL
Hermens; Willem Theodoor	Gronsveld			NL

US-CL-CURRENT: 514/2; 514/8, 530/380, 530/417

CLAIMS:

What is claimed is:

1. A therapeutic or prophylactic treatment method of acute myocardial infarction, which method comprises administering exogenous C1-esterase inhibitor, alone or in combination with other drugs, to a patient with acute myocardial infarction or to a patient at risk for acute myocardial infarction.
2. The method of claim 1 where said C1-esterase inhibitor is administered in an amount sufficient to reduce myocardial cell injury.
3. The method of claim 1 where said C1-esterase inhibitor is administered by intravenous injection, usually in an amount in the range of 30 to 40 U per kg of body weight.
4. The method of claim 1 where said C1-esterase inhibitor is C1-esterase inhibitor purified from human plasma.
5. The method of claim 1 where said C1-esterase inhibitor is C1-esterase inhibitor purified from human plasma, and thereafter modified by chemical or other manipulations with maintenance of C1-esterase inhibitor activity.
6. The method of claim 1 where said C1-esterase inhibitor is C1-esterase inhibitor purified from animal plasma.
7. The method of claim 1 where said C1-esterase inhibitor is C1-esterase inhibitor purified from animal plasma, and thereafter modified by chemical or other manipulations with maintenance of C1-esterase inhibitor activity.
8. The method of claim 1 where said C1-esterase inhibitor is C1-esterase inhibitor purified from human biological material other than plasma.
9. The method of claim 1 where said C1-esterase inhibitor is C1-esterase inhibitor purified from human biological material other than plasma, and thereafter modified by chemical or other manipulations with maintenance of C1-esterase inhibitor activity.

10. The method of claim 1 where said C1-esterase inhibitor is C1-esterase inhibitor purified from animal biological material other than plasma.

11. The method of claim 1 where said C1-esterase inhibitor is C1-esterase inhibitor purified from animal biological material other than plasma, and thereafter modified by chemical or other manipulations with maintenance of C1-esterase inhibitor activity.

12. The method of claim 1 where said C1-esterase inhibitor is recombinant C1-esterase inhibitor.

13. The method of claim 1 where said C1-esterase inhibitor is recombinant C1-esterase inhibitor modified by chemical or other manipulations with maintenance of C1-esterase inhibitor activity.

14. The method of claim 1 where said C1-esterase inhibitor is a variant of recombinant C1-esterase inhibitor in which C1-esterase inhibitor activity has been maintained.

15. The method of claim 1 where said C1-esterase inhibitor is a variant of recombinant C1-esterase inhibitor modified by chemical or other manipulations with maintenance of C1-esterase inhibitor activity.

16. The method of claim 1 where said C1-esterase inhibitor is recombinant proteinase inhibitor other than C1-esterase inhibitor, mutated to yield C1-esterase inhibitor activity.

17. The method of claim 1 where said C1-esterase inhibitor is recombinant proteinase inhibitor other than C1-esterase inhibitor, mutated to yield C1-esterase inhibitor activity and modified by chemical or other manipulations with maintenance of C1-esterase inhibitor activity.

18. The method of claim 1 where said C1-esterase inhibitor is administered in combination with a substance which improves the blood flow to the myocardium, such as tissue plasminogen activator, urokinase or streptokinase.

19. The method of claim 1 where said C1-esterase inhibitor is administered in combination with a substance having anti-inflammatory properties, such as an oxygen radical scavenger or a cytokine antagonist.

20. A pharmaceutical composition comprising exogenous C1-esterase inhibitor, a carrier and a substance capable of improving blood flow to the myocardium.

21. A pharmaceutical composition comprising exogenous C1-esterase inhibitor, a carrier and a substance having anti-inflammatory properties.

Print

[illegible]

☐ 3. Document ID: US 5278285 A

L3: Entry 3 of 4

File: USPT

Jan 11, 1994

US-PAT-NO: 5278285

DOCUMENT-IDENTIFIER: US 5278285 A

TITLE: Variant of Kunitz-type inhibitor derived from the .alpha.3-chain of human type VI collagen produced by recombinant DNA technology

DATE-ISSUED: January 11, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ebbers; Juergen	Wuppertal			DE
Hoerlein; Dietrich	Wuppertal			DE
Timpl; Ruppert	Martinsried			DE
Chu; Mon-Li	Philadelphia	PA		

US-CL-CURRENT: 530/324; 435/69.2, 930/250

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

FIND

☐ 4. Document ID: US 20020160433 A1 WO 200234918 A2 AU 200226074 A

L3: Entry 4 of 4

File: DWPI

Oct 31, 2002

DERWENT-ACC-NO: 2002-471441

DERWENT-WEEK: 200274

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: New p0157 plasmid-specified polypeptide found in Escherichia coli and other enterohemorrhagic Escherichia coli, that binds to and cleaves C1-esterase inhibitor, useful for diagnosing and treating colitis

INVENTOR: LATHEM, W W; WELCH, R A

PRIORITY-DATA: 2000US-243675P (October 26, 2000), 2001US-0002309 (October 26, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20020160433 A1	October 31, 2002		000	G01N033/569
WO 200234918 A2	May 2, 2002	E	058	C12N015/31
AU 200226074 A	May 6, 2002		000	C12N015/31

INT-CL (IPC): A61 K 39/108; C07 H 21/04; C07 K 14/245; C07 K 16/12; C12 N 1/21; C12 N 9/52; C12 N 15/31; C12 N 15/63; C12 N 15/74; C12 P 21/02; C12 Q 1/44; C12 Q 1/68; G01 N 33/569

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

FIND

Generate Collection

Print

Terms	Documents
L2 and Escherichia	4

Display Format: Change Format

[Previous Page](#) [Next Page](#)

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1814TXS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the
present
NEWS 4 AUG 05 New pricing for EUROPATFULL and PCTFULL effective
August 1, 2003
NEWS 5 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 6 AUG 18 Data available for download as a PDF in RDISCLOSURE
NEWS 7 AUG 18 Simultaneous left and right truncation added to PASCAL
NEWS 8 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right
Truncation
NEWS 9 AUG 18 Simultaneous left and right truncation added to ANABSTR
NEWS 10 SEP 22 DIPPR file reloaded
NEWS 11 SEP 25 INPADOC: Legal Status data to be reloaded
NEWS 12 SEP 29 DISSABS now available on STN
NEWS 13 OCT 10 PCTFULL: Two new display fields added

NEWS EXPRESS OCTOBER 01 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:06:27 ON 13 OCT 2003

=> file medline caplus embase biotechds biosis
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 12:07:00 ON 13 OCT 2003

FILE 'CAPLUS' ENTERED AT 12:07:00 ON 13 OCT 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 12:07:00 ON 13 OCT 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'BIOTECHDS' ENTERED AT 12:07:00 ON 13 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOSIS' ENTERED AT 12:07:00 ON 13 OCT 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

=> s Escherichia coli and C1-esterase inhibitor
L1 39 ESCHERICHIA COLI AND C1-ESTERASE INHIBITOR

=> dup rem l1
PROCESSING COMPLETED FOR L1
L2 21 DUP REM L1 (18 DUPLICATES REMOVED)

=> s l2 and p0157
L3 0 L2 AND P0157

=> s l2 and EDL933
L4 2 L2 AND EDL933

=> d l4 1-2 ibib ab

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:332346 CAPLUS

DOCUMENT NUMBER: 136:352542

TITLE: E. coli **C1 esterase inhibitor**-binding protein StcE and uses in treating colitis or hemolytic uremic syndrome

INVENTOR(S): Welch, Rodney A.; Lathem, Wyndham W.

PATENT ASSIGNEE(S): Wisconsin Alumni Research Foundation, USA

SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002034918	A2	20020502	WO 2001-US47719	20011026
WO 2002034918	A3	20030130		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002026074	A5	20020506	AU 2002-26074	20011026
---------------	----	----------	---------------	----------

US 2002160433	A1	20021031	US 2001-2309	20011026
---------------	----	----------	--------------	----------

PRIORITY APPLN. INFO.: US 2000-243675P P 20001026

WO 2001-US47719 W 20011026

AB Disclosed is a p0157 plasmid-specified polypeptide found in E. coli **EDL933** and other enterohemorrhagic E. coli that binds to and cleaves **C1-esterase inhibitor**. Also disclosed are methods employing the polypeptide for diagnosing and treating colitis or hemolytic uremic syndrome, and methods of detecting

potential therapeutics. StcE is able to cleave both purified and serum-assocd. C1 inhibitor. Mutagenesis confirms that glutamic acid 435 is necessary for both binding and cleavage of C1 inhibitor. The invention also relates to detection of StcE among diarrheagenic E. coli strain.

L4 ANSWER 2 OF 2 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 2002:176597 BIOSIS
DOCUMENT NUMBER: PREV200200176597
TITLE: StcE, a novel metalloprotease from enterohemorrhagic

Escherichia coli, is specific for
pO157-containing strains of diarrheagenic E. coli.
AUTHOR(S): Witowski, S. E. (1); Lathem, W. W. (1); Welch, R. A. (1)
CORPORATE SOURCE: (1) University of Wisconsin, Madison, WI USA
SOURCE: Abstracts of the General Meeting of the American Society
for Microbiology, (2001) Vol. 101, pp. 113.
<http://www.asmsusa.org/mtgsrc/generalmeeting.htm>. print.
Meeting Info.: 101st General Meeting of the American
Society for Microbiology Orlando, FL, USA May 20-24, 2001
ISSN: 1060-2011.

DOCUMENT TYPE: Conference

LANGUAGE: English

AB Enterohemorrhagic **Escherichia coli** (EHEC) causes
hemorrhagic colitis and hemolytic uremic syndrome. Enterohemorrhagic E.
coli strain **EDL933** produces an exoprotein, StcE, which
specifically cleaves plasma **C1 esterase**
inhibitor (C1INH). The gene responsible for this phenotype was
localized to the pO157 virulence plasmid present in **EDL933**. This
gene is found immediately 5' to the etp type II protein secretion gene
cluster. The StcE protein contains a putative cleavable N-terminal peptide
sequence and is released into the culture supernatant, suggesting that it
may be secreted through this apparatus. We sought to determine the
prevalence of stcE among other strains of diarrheagenic E. coli. The DEC
collection (Whittam et al., Infect. Immun. 61:1619-1629) was used for an
epidemiologic survey because it represents different clonal types and O:H
serotypes of diarrheagenic E. coli. PCR and Southern blot analyses were
used to establish which serotypes contained the stcE gene while Western
blot analysis and C1INH proteolysis determined the expression of the StcE
protein and its activity. Our genomic analyses show that the stcE gene is
readily found among the O157:H7 strains of E. coli, but not
enteropathogenic (EPEC) or enterotoxigenic (ETEC) strains. Immunoblotting
reveals a StcE-like product is also secreted by the other O157:H7 strains
of E. coli. Slower migrating species that cross-react with a polyclonal
StcE antibody were detected in other EHEC and O157 serotypes. This
indicates that StcE expression is common among O157:H7 strains of E. coli,
and that it may be found in other EHEC strains as well.

=> s l2 and pO157

L5 4 L2 AND PO157

=> d l5 1-4 ibib ab

L5 ANSWER 1 OF 4 MEDLINE on STN
ACCESSION NUMBER: 2002378601 MEDLINE
DOCUMENT NUMBER: 22120277 PubMed ID: 12123444
TITLE: StcE, a metalloprotease secreted by **Escherichia**
coli O157:H7, specifically cleaves C1
esterase inhibitor.

AUTHOR: Lathem Wyndham W; Grys Thomas E; Witowski Sarah E; Torres
Alfredo G; Kaper James B; Tarr Phillip I; Welch Rodney A
CORPORATE SOURCE: Department of Medical Microbiology and Immunology,
University of Wisconsin, Madison, WI 53706, USA.
CONTRACT NUMBER: AI20323 (NIAID)
AI41325 (NIAID)

DK52081 (NIDDK)
DK58957 (NIDDK)

SOURCE: MOLECULAR MICROBIOLOGY, (2002 Jul) 45 (2) 277-88.
Journal code: 8712028. ISSN: 0950-382X.
PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200209
ENTRY DATE: Entered STN: 20020719
Last Updated on STN: 20020928
Entered Medline: 20020927

AB **Escherichia coli** O157:H7 causes diarrhoea, haemorrhagic colitis, and the haemolytic uraemic syndrome. We have identified a protein of previously unknown function encoded on the **pO157** virulence plasmid of *E. coli* O157:H7, which is the first described protease that specifically cleaves **C1 esterase inhibitor** (C1-INH), a member of the serine protease inhibitor family. The protein, named StcE for secreted protease of **C1 esterase inhibitor** from EHEC (formerly Tagn), cleaves C1-INH to produce (unique) approximately 60-65 kDa fragments. StcE does not digest other serine protease inhibitors, extracellular matrix proteins or universal protease targets. We also observed that StcE causes the aggregation of cultured human T cells but not macrophage-like cells or B cells. Substitution of aspartic acid for glutamic acid at StcE position 435 within the consensus metalloprotease active site ablates its abilities to digest C1-INH and to aggregate T cells. StcE is secreted by the etp type II secretion pathway encoded on **pO157**, and extracellular StcE levels are positively regulated by the LEE-encoded regulator, Ler. StcE antigen and activity were detected in the faeces of a child with an *E. coli* O157:H7 infection, demonstrating the expression of StcE during human disease. Cleavage of C1-INH by StcE could plausibly cause localized pro-inflammatory and coagulation responses resulting in tissue damage, intestinal oedema and thrombotic abnormalities.

L5 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:332346 CAPLUS
DOCUMENT NUMBER: 136:352542
TITLE: *E. coli* **C1 esterase inhibitor**-binding protein StcE and uses in treating colitis or hemolytic uremic syndrome
INVENTOR(S): Welch, Rodney A.; Lathem, Wyndham W.
PATENT ASSIGNEE(S): Wisconsin Alumni Research Foundation, USA
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002034918	A2	20020502	WO 2001-US47719	20011026
WO 2002034918	A3	20030130		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002026074	A5	20020506	AU 2002-26074	20011026

US 2002160433 A1 20021031 US 2001-2309 20011026
PRIORITY APPLN. INFO.: US 2000-243675P P 20001026
WO 2001-US47719 W 20011026

AB Disclosed is a **p0157** plasmid-specified polypeptide found in *E. coli* EDL933 and other enterohemorrhagic *E. coli* that binds to and cleaves **C1-esterase inhibitor**. Also disclosed are methods employing the polypeptide for diagnosing and treating colitis or hemolytic uremic syndrome, and methods of detecting potential therapeutics. StcE is able to cleave both purified and serum-assocd. C1 inhibitor. Mutagenesis confirms that glutamic acid 435 is necessary for both binding and cleavage of C1 inhibitor. The invention also relates to detection of StcE among diarrheagenic *E. coli* strain.

L5 ANSWER 3 OF 4 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN

ACCESSION NUMBER: 2002:176600 BIOSIS

DOCUMENT NUMBER: PREV200200176600

TITLE: A novel metalloprotease secreted by **Escherichia coli** O157:H7 cleaves **C1 esterase inhibitor**, a regulator of multiple proteolytic cascades.

AUTHOR(S): Lathem, W. W. (1); Welch, R. A. (1)

CORPORATE SOURCE: (1) University of Wisconsin, Madison, WI USA

SOURCE: Abstracts of the General Meeting of the American Society for Microbiology, (2001) Vol. 101, pp. 113.
<http://www.asmsusa.org/mtgsrc/generalmeeting.htm>. print.
Meeting Info.: 101st General Meeting of the American Society for Microbiology Orlando, FL, USA May 20-24, 2001
ISSN: 1060-2011.

DOCUMENT TYPE: Conference

LANGUAGE: English

AB Enterohemorrhagic **Escherichia coli** (EHEC) are responsible for diarrheal disease, hemorrhagic colitis, and hemolytic uremic syndrome that can lead to acute renal failure and death. Strains of the serotype O157:H7 carry a large virulence plasmid designated **p0157** that encodes genes for multiple virulence factors. We have identified a gene on **p0157** of previous unknown function whose product causes the serum-dependent aggregation of two cultured human CD4+ T cell lines, Jurkat and MOLT-4, but not a B cell lymphoma line (Raji), or macrophage-like cell lines (U937 and HL-60). The protein, named StcE for secreted T cell aggregation factor from EHEC, contains a putative N-terminal signal sequence and lies immediately upstream of the etp type II protein secretion cluster of **p0157**. A recombinant form of StcE (StcE-His) interacts with a human serum protein(s) of approximately 105 kDa as determined by Far Western blotting analysis. This protein was identified by mass spectrometry as plasma **C1 esterase inhibitor** (C1INH). C1INH is a regulatory protein responsible for controlling several proteolytic cascades, including the classical complement pathway. StcE-His specifically cleaves purified C1INH to produce an approximately 60 kDa fragment in a zinc-dependent manner; StcE-His also acts on C1INH in human serum. Additionally, bacterial culture supernatants containing native StcE cleave C1INH as described. StcE may represent a new class of bacterial virulence factors termed inserpins (inhibitors of serine protease inhibitors) which act to disregulate the host's ability to control the inappropriate activation of the complement, kallikrein, and coagulation cascades. This may result in an unregulated pro-inflammatory and coagulation response that may be responsible for tissue damage in the intestine and kidney in patients infected with enterohemorrhagic strains of *E. coli*.

L5 ANSWER 4 OF 4 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN

ACCESSION NUMBER: 2002:176597 BIOSIS

DOCUMENT NUMBER: PREV200200176597

TITLE: StcE, a novel metalloprotease from enterohemorrhagic **Escherichia coli**, is specific for

AUTHOR(S): p0157-containing strains of diarrheagenic E. coli.
 Witowski, S. E. (1); Lathem, W. W. (1); Welch, R. A. (1)
 CORPORATE SOURCE: (1) University of Wisconsin, Madison, WI USA
 SOURCE: Abstracts of the General Meeting of the American Society
 for Microbiology, (2001) Vol. 101, pp. 113.
<http://www.asmusa.org/mtgsrsrc/generalmeeting.htm>. print.
 Meeting Info.: 101st General Meeting of the American
 Society for Microbiology Orlando, FL, USA May 20-24, 2001
 ISSN: 1060-2011.

DOCUMENT TYPE: Conference
 LANGUAGE: English

AB Enterohemorrhagic **Escherichia coli** (EHEC) causes
 hemorrhagic colitis and hemolytic uremic syndrome. Enterohemorrhagic E.
 coli strain EDL933 produces an exoprotein, StcE, which specifically
 cleaves plasma C1 **esterase inhibitor**
 (C1INH). The gene responsible for this phenotype was localized to the
 p0157 virulence plasmid present in EDL933. This gene is found
 immediately 5' to the etp type II protein secretion gene cluster. The StcE
 protein contains a putative cleavable N-terminal peptide sequence and is
 released into the culture supernatant, suggesting that it may be secreted
 through this apparatus. We sought to determine the prevalence of stcE
 among other strains of diarrheagenic E. coli. The DEC collection (Whittam
 et al., Infect. Immun. 61:1619-1629) was used for an epidemiologic survey
 because it represents different clonal types and O:H serotypes of
 diarrheagenic E. coli. PCR and Southern blot analyses were used to
 establish which serotypes contained the stcE gene while Western blot
 analysis and C1INH proteolysis determined the expression of the StcE
 protein and its activity. Our genomic analyses show that the stcE gene is
 readily found among the O157:H7 strains of E. coli, but not
 enteropathogenic (EPEC) or enterotoxigenic (ETEC) strains. Immunoblotting
 reveals a StcE-like product is also secreted by the other O157:H7 strains
 of E. coli. Slower migrating species that cross-react with a polyclonal
 StcE antibody were detected in other EHEC and O157 serotypes. This
 indicates that StcE expression is common among O157:H7 strains of E. coli,
 and that it may be found in other EHEC strains as well.

=> focus l2
 PROCESSING COMPLETED FOR L2
 L6 21 FOCUS L2 1-

=> d l6 1-10 ibib ab

L6 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1988:584958 CAPLUS
 DOCUMENT NUMBER: 109:184958
 TITLE: Cloning and sequencing of human C1
esterase inhibitor cDNA, and use of
 inhibitor in treatment of and inhibitor DNA in
 diagnosis of hereditary angiodema
 INVENTOR(S): Tosi, Mario; Duponchel, Christiane; Meo, Tommaso
 PATENT ASSIGNEE(S): Institut Pasteur, Fr.; Institut National de la Sante
 et de la Recherche Medicale (INSERM)
 SOURCE: Fr. Demande, 26 pp.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2601034	A1	19880108	FR 1986-9662	19860703
FR 2601034	B1	19891117		

PRIORITY APPLN. INFO.: FR 1986-9662 19860703

AB The human **C1 esterase inhibitor** (CEN) cDNA is cloned and sequenced. The CEN DNA, CEN, and antibodies to CEN are useful for diagnosis of hereditary angioedema and CEN can be used to treat the disease. The CEN cDNA of human liver was cloned in **Escherichia coli**. Its amino acid sequence was 27% identical with that of human .alpha.1-antitrypsin and 23% with that of human antithrombin III.

L6 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:332346 CAPLUS

DOCUMENT NUMBER: 136:352542

TITLE: E. coli **C1 esterase inhibitor**-binding protein StcE and uses in treating colitis or hemolytic uremic syndrome

INVENTOR(S): Welch, Rodney A.; Lathem, Wyndham W.

PATENT ASSIGNEE(S): Wisconsin Alumni Research Foundation, USA

SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002034918	A2	20020502	WO 2001-US47719	20011026
WO 2002034918	A3	20030130		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002026074	A5	20020506	AU 2002-26074	20011026
US 2002160433	A1	20021031	US 2001-2309	20011026

PRIORITY APPLN. INFO.: US 2000-243675P P 20001026
WO 2001-US47719 W 20011026

AB Disclosed is a pO157 plasmid-specified polypeptide found in E. coli EDL933 and other enterohemorrhagic E. coli that binds to and cleaves **C1 -esterase inhibitor**. Also disclosed are methods employing the polypeptide for diagnosing and treating colitis or hemolytic uremic syndrome, and methods of detecting potential therapeutics. StcE is able to cleave both purified and serum-assocd. C1 inhibitor. Mutagenesis confirms that glutamic acid 435 is necessary for both binding and cleavage of C1 inhibitor. The invention also relates to detection of StcE among diarrheagenic E. coli strain.

L6 ANSWER 3 OF 21 MEDLINE on STN

ACCESSION NUMBER: 2002378601 MEDLINE

DOCUMENT NUMBER: 22120277 PubMed ID: 12123444

TITLE: StcE, a metalloprotease secreted by **Escherichia coli** O157:H7, specifically cleaves **C1 esterase inhibitor**.

AUTHOR: Lathem Wyndham W; Grys Thomas E; Witowski Sarah E; Torres Alfredo G; Kaper James B; Tarr Phillip I; Welch Rodney A

CORPORATE SOURCE: Department of Medical Microbiology and Immunology, University of Wisconsin, Madison, WI 53706, USA.

CONTRACT NUMBER: AI20323 (NIAID)

AI41325 (NIAID)

DK52081 (NIDDK)

DK58957 (NIDDK)

SOURCE: MOLECULAR MICROBIOLOGY, (2002 Jul) 45 (2) 277-88.
Journal code: 8712028. ISSN: 0950-382X.
PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200209
ENTRY DATE: Entered STN: 20020719
Last Updated on STN: 20020928
Entered Medline: 20020927

AB **Escherichia coli** O157:H7 causes diarrhoea, haemorrhagic colitis, and the haemolytic uraemic syndrome. We have identified a protein of previously unknown function encoded on the pO157 virulence plasmid of *E. coli* O157:H7, which is the first described protease that specifically cleaves **C1 esterase inhibitor** (C1-INH), a member of the serine protease inhibitor family. The protein, named StcE for secreted protease of **C1 esterase inhibitor** from EHEC (formerly Tagn), cleaves C1-INH to produce (unique) approximately 60-65 kDa fragments. StcE does not digest other serine protease inhibitors, extracellular matrix proteins or universal protease targets. We also observed that StcE causes the aggregation of cultured human T cells but not macrophage-like cells or B cells. Substitution of aspartic acid for glutamic acid at StcE position 435 within the consensus metalloprotease active site ablates its abilities to digest C1-INH and to aggregate T cells. StcE is secreted by the etp type II secretion pathway encoded on pO157, and extracellular StcE levels are positively regulated by the LEE-encoded regulator, Ler. StcE antigen and activity were detected in the faeces of a child with an *E. coli* O157:H7 infection, demonstrating the expression of StcE during human disease. Cleavage of C1-INH by StcE could plausibly cause localized pro-inflammatory and coagulation responses resulting in tissue damage, intestinal oedema and thrombotic abnormalities.

L6 ANSWER 4 OF 21 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN

ACCESSION NUMBER: 2002:176600 BIOSIS
DOCUMENT NUMBER: PREV200200176600
TITLE: A novel metalloprotease secreted by **Escherichia coli** O157:H7 cleaves **C1 esterase inhibitor**, a regulator of multiple proteolytic cascades.

AUTHOR(S): Lathem, W. W. (1); Welch, R. A. (1)
CORPORATE SOURCE: (1) University of Wisconsin, Madison, WI USA
SOURCE: Abstracts of the General Meeting of the American Society for Microbiology, (2001) Vol. 101, pp. 113.
<http://www.asmta.org/mtgsrc/generalmeeting.htm>. print.
Meeting Info.: 101st General Meeting of the American Society for Microbiology Orlando, FL, USA May 20-24, 2001
ISSN: 1060-2011.

DOCUMENT TYPE: Conference
LANGUAGE: English

AB Enterohemorrhagic **Escherichia coli** (EHEC) are responsible for diarrheal disease, hemorrhagic colitis, and hemolytic uremic syndrome that can lead to acute renal failure and death. Strains of the serotype O157:H7 carry a large virulence plasmid designated pO157 that encodes genes for multiple virulence factors. We have identified a gene on pO157 of previous unknown function whose product causes the serum-dependent aggregation of two cultured human CD4+ T cell lines, Jurkat and MOLT-4, but not a B cell lymphoma line (Raji), or macrophage-like cell lines (U937 and HL-60). The protein, named StcE for secreted T cell aggregation factor from EHEC, contains a putative N-terminal signal sequence and lies immediately upstream of the etp type II protein secretion cluster of pO157. A recombinant form of StcE (StcE-His) interacts with a human serum protein(s) of approximately 105

kDa as determined by Far Western blotting analysis. This protein was identified by mass spectrometry as plasma **C1 esterase inhibitor** (C1INH). C1INH is a regulatory protein responsible for controlling several proteolytic cascades, including the classical complement pathway. StcE-His specifically cleaves purified C1INH to produce an approximately 60 kDa fragment in a zinc-dependent manner; StcE-His also acts on C1INH in human serum. Additionally, bacterial culture supernatants containing native StcE cleave C1INH as described. StcE may represent a new class of bacterial virulence factors termed inserpins (inhibitors of serine protease inhibitors) which act to disregulate the host's ability to control the inappropriate activation of the complement, kallikrein, and coagulation cascades. This may result in an unregulated pro-inflammatory and coagulation response that may be responsible for tissue damage in the intestine and kidney in patients infected with enterohemorrhagic strains of *E. coli*.

L6 ANSWER 5 OF 21 MEDLINE on STN
 ACCESSION NUMBER: 1999213634 MEDLINE
 DOCUMENT NUMBER: 99213634 PubMed ID: 10199542
 TITLE: Combined antithrombin III and **C1-esterase inhibitor** treatment decreases intravascular fibrin deposition and attenuates cardiorespiratory impairment in rabbits exposed to **Escherichia coli** endotoxin.
 AUTHOR: Giebler R; Schmidt U; Koch S; Peters J; Scherer R
 CORPORATE SOURCE: Abteilung fur Anesthesiologie und Intensivmedizin, Klinikum der Universitat-GH Essen, Germany.
 SOURCE: CRITICAL CARE MEDICINE, (1999 Mar) 27 (3) 597-604.
 Journal code: 0355501. ISSN: 0090-3493.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
 ENTRY MONTH: 199904
 ENTRY DATE: Entered STN: 19990511
 Last Updated on STN: 19990511
 Entered Medline: 19990427
 AB OBJECTIVE: To assess the effect of a combined antithrombin III and **C1-esterase inhibitor** treatment on intravascular organ fibrin deposition and cardiorespiratory changes following intravenous **Escherichia coli** endotoxin (lipopolysaccharide [LPS] 80 microg/kg i.v.) exposure. DESIGN: Prospective, randomized trial. SETTING: Research laboratory of a university medical center. SUBJECTS: Anesthetized, instrumented and mechanically ventilated rabbits ([Chbb:CH]; n = 40). INTERVENTIONS: Endotoxin was given to 30 animals. Ten animals received no inhibitor (endotoxin control group). The other animals were either treated by high-dose (300 units/kg; n = 10) or low-dose (100 units/kg; n = 10) combined antithrombin III and **C1-esterase inhibitor** administration. Ten rabbits (time control group) were given placebo (sodium chloride 0.9%). Cardiorespiratory variables were assessed at baseline, 120 mins, and 240 mins after endotoxin or placebo administration. Four hours after endotoxin injection, liver, lung, and kidney tissue samples were examined for intravascular fibrin deposition by light microscopy. MEASUREMENTS AND MAIN RESULTS: Inhibitor treatment significantly decreased clot formation in lungs and livers without, however, demonstrating a clear dose-dependent effect. Combined antithrombin III/C1-esterase treatment attenuated the decrease of mean arterial pressure and cardiac output observed following endotoxin injection. Blood pressure improvement was significantly dependent on dosage administered. CONCLUSION: Combination of antithrombin III and **C1-esterase inhibitor** treatment during early endotoxin shock decreased organ fibrin deposition and improved cardiovascular stability.

L6 ANSWER 6 OF 21 MEDLINE on STN
 ACCESSION NUMBER: 2003265655 MEDLINE
 DOCUMENT NUMBER: 22676519 PubMed ID: 12792867
 TITLE: Acquisition of **stcE**, a **C1 esterase inhibitor**-specific metalloprotease, during the evolution of **Escherichia coli** O157:H7.
 AUTHOR: Lathem Wyndham W; Bergsbaken Tessa; Witowski Sarah E; Perna Nicole T; Welch Rodney A
 CORPORATE SOURCE: Department of Medical Microbiology and Immunology, University of Wisconsin, Madison, Wisconsin, USA.
 CONTRACT NUMBER: AI20323 (NIAID)
 AI51735 (NIAID)
 SOURCE: JOURNAL OF INFECTIOUS DISEASES, (2003 Jun 15) 187 (12) 1907-14.
 Journal code: 0413675. ISSN: 0022-1899.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
 ENTRY MONTH: 200307
 ENTRY DATE: Entered STN: 20030608
 Last Updated on STN: 20030725
 Entered Medline: 20030724

AB **Escherichia coli** O157:H7 is a source of foodborne illness, causing diarrhea, hemorrhagic colitis, and hemolytic-uremic syndrome. *E. coli* O157:H7 secretes, via the *etp* type II secretion system, a metalloprotease, *StcE*, that specifically cleaves the serpin **C1 esterase inhibitor**. We determined by hybridization techniques the prevalence of *stcE* and *etpD*, a type II secretion gene, among diarrheagenic *E. coli* strains. *stcE* and *etpD* are ubiquitous among the O157:H7 serotype and are found in some enteropathogenic *E. coli* O55:H7 strains but are absent from other diarrheagenic *E. coli*. *stcE* was acquired on a large plasmid early in the evolution of *E. coli* O157:H7, before the inheritance of the Shiga toxin prophage. Other plasmidborne virulence factors, such as *ehxA*, *katP*, and *espP*, were acquired later by the enterohemorrhagic *E. coli* 1 complex in a stepwise manner. These data refine the sequential model of *E. coli* O157:H7 evolution proposed elsewhere.

L6 ANSWER 7 OF 21 MEDLINE on STN
 ACCESSION NUMBER: 1999175908 MEDLINE
 DOCUMENT NUMBER: 99175908 PubMed ID: 10076612
 TITLE: **C1-esterase inhibitor** and its effects on endotoxin-induced leukocyte adherence and plasma extravasation in postcapillary venules.
 AUTHOR: Schmidt W; Stenzel K; Gebhard M M; Martin E; Schmidt H
 CORPORATE SOURCE: Department of Anesthesiology, University of Heidelberg, Germany.
 SOURCE: SURGERY, (1999 Mar) 125 (3) 280-7.
 Journal code: 0417347. ISSN: 0039-6060.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
 ENTRY MONTH: 199903
 ENTRY DATE: Entered STN: 19990402
 Last Updated on STN: 19990402
 Entered Medline: 19990324

AB BACKGROUND: **C1-esterase inhibitor** (C1-INH) has been shown to have beneficial effects in patients with sepsis. However, the microcirculatory effects of C1-INH during sepsis are unknown. This study investigated the influence of C1-INH on leukocyte-endothelial cell adhesion, vascular leakage, and venular microhemodynamics in

postcapillary venules of rat mesentery during endotoxemia. METHODS: Thirty-two anesthetized Wistar rats randomly received 1 of 4 treatments: pretreatment with infusion of C1-INH in a concentration of 7.5 U.kg-1 body weight (C1-INH-7.5 group, n = 8) or in a concentration of 15 U.kg-1 body weight (C1-INH-15 group, n = 8) followed by continuous infusion of **Escherichia coli** lipopolysaccharide (LPS). The LPS group (n = 8) was pretreated with saline solution 30 minutes before LPS infusion. The control group (n = 8) received equivalent amounts of saline infusion. Leukocyte adherence, red blood cell velocity, and vessel diameters in postcapillary venules of rat mesentery were determined every 60 minutes during a period of 120 minutes using in vivo videomicroscopy. Vascular permeability was determined by measuring the extravasation of fluorescence-labeled albumin. Venular wall shear rate was calculated from mean red blood cell velocity and vessel diameter. RESULTS: LPS infusion induced a decrease in venular wall shear rate and an increase in leukocyte adherence and vascular permeability in postcapillary venules of rat mesentery. All microcirculatory disturbances were attenuated by pretreatment with C1-INH, showing no significant difference between the 2 concentrations. CONCLUSIONS: Pretreatment with C1-INH attenuates endotoxin-induced leukocyte adherence and macromolecular leakage in postcapillary venules of rat mesentery, indicating that complement inhibition might be a therapeutic tool in the treatment of sepsis.

L6 ANSWER 8 OF 21 MEDLINE on STN
 ACCESSION NUMBER: 93294014 MEDLINE
 DOCUMENT NUMBER: 93294014 PubMed ID: 8514883
 TITLE: Endotoxin-induced pulmonary dysfunction is prevented by **C1-esterase inhibitor**.
 AUTHOR: Guerrero R; Velasco F; Rodriguez M; Lopez A; Rojas R; Alvarez M A; Villalba R; Rubio V; Torres A; del Castillo D
 CORPORATE SOURCE: Unidad de Investigacion, Hospital Universitario Reina Sofia, Spain.
 SOURCE: JOURNAL OF CLINICAL INVESTIGATION, (1993 Jun) 91 (6) 2754-60.
 Journal code: 7802877. ISSN: 0021-9738.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
 ENTRY MONTH: 199307
 ENTRY DATE: Entered STN: 19930806
 Last Updated on STN: 19930806
 Entered Medline: 19930721

AB In septic shock, hypotension, disseminated intravascular coagulation, and neutrophil activation are related to the activation of the blood coagulation contact system. This study evaluates in dogs the effect of the **C1-esterase inhibitor** (C1-INH), a main inhibitor of the blood coagulation contact system, on the cardiovascular and respiratory dysfunction associated with endotoxic shock. Two groups were included: controls, which received **Escherichia coli** endotoxin, and a C1-INH group in which C1-INH was infused before E. coli endotoxin administration. In both groups, endotoxin produced hypodynamic shock; however, the decrease in the systolic index and the ventricular systolic work indexes were greater in controls than the C1-INH group. In controls, the arterial O2 partial pressure decreased by 30% and the alveolo-arterial O2 difference increased by 625%, these parameters remained unchanged in the C1-INH group. Hypoxemia was associated with increased intrapulmonary shunt, decreased blood coagulation contact factors, and decreased C3c. In contrast, C1-INH administration prevented endotoxin-induced hypoxemia, the increase in intrapulmonary shunt, and the decrease in blood coagulation contact factors. This study shows that, in dogs with endotoxic shock, pulmonary dysfunction is associated with an activation of the blood coagulation contact phase system. An inhibition of this system by C1-INH prevented the hypoxemia induced by endotoxic

shock.

L6 ANSWER 9 OF 21 MEDLINE on STN
ACCESSION NUMBER: 97099853 MEDLINE
DOCUMENT NUMBER: 97099853 PubMed ID: 8944422
TITLE: The influence of **C1-esterase inhibitor** substitution on coagulation and cardiorespiratory parameters in an endotoxin-induced rabbit model of hypercoagulability.
AUTHOR: Scherer R U; Giebler R M; Schmidt U; Paar D; Kox W J
CORPORATE SOURCE: Department of Anesthesiology and Intensive Care, University Hospital Essen, Germany.
SOURCE: SEMINARS IN THROMBOSIS AND HEMOSTASIS, (1996) 22 (4) 357-66.
Journal code: 0431155. ISSN: 0094-6176.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199702
ENTRY DATE: Entered STN: 19970313
Last Updated on STN: 19970313
Entered Medline: 19970228

AB In a short-time model of endotoxin-induced (lipopolysaccharide from **Escherichia coli**, 120 micrograms kg⁻¹ i.v.) hypercoagulability in rabbits, the therapeutic effects of **C1-esterase inhibitor** (C1I) substitution (bolus 400 U kg⁻¹ i.v. followed by continuous infusion of 400 U kg⁻¹ 4 h⁻¹ i.v.) were studied. When compared to endotoxin-challenged untreated animals, C1I substitution significantly stabilized mean arterial pressure (p < 0.01), increased central venous oxygen saturation (p < 0.05), prevented the decrease of antithrombin III (p < 0.05), and reduced fibrin deposition in the microcirculation of the liver and the lungs to approximately 30% of that observed in the untreated animals (p < 0.01). Although C1I substitution did not reduce systemic procoagulant turnover, the improvement of blood pressure and blood flow and local inhibitory actions in the coagulation and complement cascade prevented fibrin deposition in the microcirculation of vital organs. This study supports the beneficial role of C1I substitution during early disseminated intravascular coagulation.

L6 ANSWER 10 OF 21 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 2002:176597 BIOSIS
DOCUMENT NUMBER: PREV200200176597
TITLE: StcE, a novel metalloprotease from enterohemorrhagic **Escherichia coli**, is specific for pO157-containing strains of diarrheagenic E. coli.
AUTHOR(S): Witowski, S. E. (1); Lathem, W. W. (1); Welch, R. A. (1)
CORPORATE SOURCE: (1) University of Wisconsin, Madison, WI USA
SOURCE: Abstracts of the General Meeting of the American Society for Microbiology, (2001) Vol. 101, pp. 113.
<http://www.asmsusa.org/mtgsrc/generalmeeting.htm>. print.
Meeting Info.: 101st General Meeting of the American Society for Microbiology Orlando, FL, USA May 20-24, 2001
ISSN: 1060-2011.
DOCUMENT TYPE: Conference
LANGUAGE: English

AB Enterohemorrhagic **Escherichia coli** (EHEC) causes hemorrhagic colitis and hemolytic uremic syndrome. Enterohemorrhagic E. coli strain EDL933 produces an exoprotein, StcE, which specifically cleaves plasma **C1 esterase inhibitor** (C1INH). The gene responsible for this phenotype was localized to the pO157 virulence plasmid present in EDL933. This gene is found immediately 5' to the etp type II protein secretion gene cluster. The StcE protein

contains a putative cleavable N-terminal peptide sequence and is released into the culture supernatant, suggesting that it may be secreted through this apparatus. We sought to determine the prevalence of stcE among other strains of diarrheagenic E. coli. The DEC collection (Whittam et al., Infect. Immun. 61:1619-1629) was used for an epidemiologic survey because it represents different clonal types and O:H serotypes of diarrheagenic E. coli. PCR and Southern blot analyses were used to establish which serotypes contained the stcE gene while Western blot analysis and C1INH proteolysis determined the expression of the StcE protein and its activity. Our genomic analyses show that the stcE gene is readily found among the O157:H7 strains of E. coli, but not enteropathogenic (EPEC) or enterotoxigenic (ETEC) strains. Immunoblotting reveals a StcE-like product is also secreted by the other O157:H7 strains of E. coli. Slower migrating species that cross-react with a polyclonal StcE antibody were detected in other EHEC and O157 serotypes. This indicates that StcE expression is common among O157:H7 strains of E. coli, and that it may be found in other EHEC strains as well.

=> d his

(FILE 'HOME' ENTERED AT 12:06:27 ON 13 OCT 2003)

FILE 'MEDLINE, CAPLUS, EMBASE, BIOTECHDS, BIOSIS' ENTERED AT 12:07:00 ON 13 OCT 2003

L1	39 S ESCHERICHIA COLI AND C1-ESTERASE INHIBITOR
L2	21 DUP REM L1 (18 DUPLICATES REMOVED)
L3	0 S L2 AND P0157
L4	2 S L2 AND EDL933
L5	4 S L2 AND P0157
L6	21 FOCUS L2 1-